In summary, this is the first report that a novel NLRP1-ASC-caspase-8 non-canonical inflammasome is activated in the cortex of mice during inflammaging and that targeting this complex with anti-ASC is a promising therapy to decrease inflammation due to aging and treat other neurodegenerative conditions like AD. Here, NLRP1 is linked to Alzheimer disease.